|
"許駿"的相關文件
顯示項目 36-85 / 148 (共3頁)
1 2 3 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2014 |
Development of GADD45 beta (growth arrest DNA damage-inducible gene 45 beta) agonists for the treatment of hepatocellular carcinoma (HCC)
|
Hsu, Chiun; Ou, Da-Liang; Chen, Kuen-Feng; Lin, Zhong-Zhe; Cheng, Ann-Lii; Shiau, Chung-Wai; 林宗哲; 鄭安理; 許駿; 陳昆鋒; 歐大諒 |
| 國立臺灣大學 |
2014 |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang, Ming-Chu; Chen, Chien-Hung; Liang, Ja-Der; Tien, Yu-Wen; Hsu, Chiun; Wong, Jau-Min; Chang, Yu-Ting; 翁昭旼; 許駿; 章明珠; 田郁文; 陳健弘; 張毓廷; 梁嘉德 |
| 國立臺灣大學 |
2014 |
Strategy for Preventing Hepatitis B Reactivation in Patients With Resolved Hepatitis B Virus Infection After Rituximab-Containing Chemotherapy Reply
|
Hsu, Chiun; Chen, Pei-Jer; Cheng, Ann-Lii; 鄭安理; 許駿 |
| 國立臺灣大學 |
2014 |
PREVENTION OF CHEMOTHERAPY-INDUCED HBV-RELATED HEPATITIS FLARE IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION: COST ANALYSIS
|
Tsou, H. -H.; Yang, H. -C.; Chuang, M. -H.; Wu, H. -Y.; Hsu, Y. -T.; Chang, W. -J.; Hsiao, C. -F.; Hsu, C.; 許駿 |
| 國立臺灣大學 |
2013 |
14-3-3 epsilon Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma
|
Liu, Tzu-An; Jan, Yee-Jee; Ko, Bor-Sheng; Liang, Shu-Man; Chen, Shyh-Chang; Wang, John; Hsu, Chiun; Wu, Yao-Ming; Liou, Jun-Yang; 柯博升; 許駿; 吳耀銘 |
| 國立臺灣大學 |
2013 |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Chen, I. C.; Hsu, C.; Chen, Y. C.; Chien, S. F.; Kao, H. F.; Chang, S. Y.; Hu, F. C.; Yeh, K. H.; 許駿; 葉坤輝; 陳宜君 |
| 國立臺灣大學 |
2013 |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression (vol 15, pg 265, 2012)
|
Hsu, Chiun; Shen, Ying-Chun; Cheng, Chia-Chi; Cheng, Ann-Lii; Hu, Fu-Chang; Yeh, Kun-Huei; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2013 |
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
|
Hsu, Chih-Hung; Kang, Yoon Koo; Yang, Tsai-Shen; Shun, Chia-Tung; Shao, Yu-Yun; Su, Wu-Chou; Sandoval-Tan, Jennifer; Chiou, Tzeon-Jye; Jin, Kate; Hsu, Chiun; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 許駿; 孫家棟 |
| 國立臺灣大學 |
2013 |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Ou, Da-Liang; Lee, Bin-Shyun; Chang, Ya-Chi; Lin, Liang-In; Liou, Jun-Yang; Hsu, Chiun; Cheng, Ann-Lii; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2013 |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen, Wei-Wu; Chang, Dwan-Ying; Huang, Shu-Min; Lin, Ching-Hung; Hsu, Chun; Lin, Ming-Hwai; Huang, Chiun-Shen; Lu, Yen-Shen; Cheng, Ann-Lii; 陳偉武; 盧彥伸; 鄭安理; 許駿; 黃俊升; 張端瑩; 林璟宏 |
| 國立臺灣大學 |
2013 |
Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size
|
Lin, Zhong-Zhe; Shau, Wen-Yi; Hsu, Chiun; Shao, Yu-Yun; Yeh, Yi-Chun; Kuo, Raymond Nien-Chen; Hsu, Chih-Hung; Yang, James Chih-Hsin; Cheng, Ann-Lii; Lai, Mei-Shu; 楊志新; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2013 |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao, Yu-Yun; Liang, Po-Chin; Wu, Yao-Ming; Huang, Chun-Chieh; Huang, Kai-Wen; Cheng, Jason C.; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; Lin, Zhong-Zhe; 邵幼雲; 林宗哲; 鄭安理; 成佳憲; 黃凱文; 徐志宏; 許駿; 梁博欽; 吳耀銘 |
| 國立臺灣大學 |
2013 |
Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.
|
Lin, Zhong-Zhe; Shau, Wen-Yi; Shao, Yu Yun; Yeh, Yi-Chun; Kuo, Raymond Nien-Chen; Hsu, Chiun; Hsu, Chih-Hung; Cheng, Ann-Lii; Lai, Mei-Shu; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿; 郭年真 |
| 國立臺灣大學 |
2013 |
Potential synergistic antitumor activity between sorafenib and lenalidomide in an orthotopic murine liver cancer model.
|
Chang, Chun-Jung; Ou, Da-Liang; Lin, Yi-Jang; Cheng, Ann-Lii; Hsu, Chiun; 張純榮; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2013 |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen, Y-C; Ou, D-L; Hsu, C.; Lin, K-L; Chang, C-Y; Lin, C-Y; Liu, S-H; Cheng, A-L; 劉興華; 鄭安理; 許駿; 歐大諒; 林靖愉 |
| 國立臺灣大學 |
2012 |
PHASE II STUDY OF CONCOMITANT THALIDOMIDE DURING RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA
|
Ch' ang, Hui-Ju; Hsu, Chiun; Chen, Chien-Hung; Chang, Ya-Hui; Chang, Jeffrey S.; Chen, Li-Tzong; 許駿; 陳健弘 |
| 國立臺灣大學 |
2012 |
Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
|
Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chiun; Lee, Kuan-Der; Hsiao, Chi-Huang; Lu, Yen-Shen; Huang, Chien-Chung; Shen, Yin-Chun; Hsu, Chih-Hung; Cheng, Ann-Lii; 盧彥伸; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2012 |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu, Chiun; Yang, Tsai-Sheng; Huo, Teh-Ia; Hsieh, Ruey-Kuen; Yu, Chih-Wei; Hwang, Wei-Shou; Hsieh, Tsai-Yuan; Huang, Wen-Tsung; Chao, Yee; Meng, Robin; Cheng, Ann-Lii; 鄭安理; 許駿; 游治維 |
| 國立臺灣大學 |
2012 |
A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression
|
Shen, Ying-Chun; Hsu, Chiun; Cheng, Chia-Chi; Hu, Fu-Chang; Cheng, Ann-Lii; 鄭安理; 許駿; 胡賦強 |
| 國立臺灣大學 |
2012 |
Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy
|
Lin, Zhong-Zhe; Hsu, Chiun; Hu, Fu-Chang; Shao, Yu-Yun; Chang, Dwan-Ying; Yang, Chih-Hsin; Hong, Ruey-Long; Hsu, Chih-Hung; Cheng, Ann-Lii; 楊志新; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 洪瑞隆; 許駿; 胡賦強; 張端瑩 |
| 國立臺灣大學 |
2012 |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression
|
Hsu, Chiun; Shen, Ying-Chun; Cheng, Chia-Chi; Cheng, Ann-Lii; Hu, Fu-Chang; Yeh, Kun-Huei; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2012 |
Metastasectomy of Krukenberg Tumors May Be Associated with Survival Benefits in Patients with Metastatic Gastric Cancer
|
Lu, Li-Chun; Shao, Yu-Yun; Hsu, Chih-Hung; Hsu, Chun; Cheng, Wen-Fang; Lin, Yu-Lin; Cheng, Ann-Lii; Yeh, Kun-Huei; 鄭文芳; 邵幼雲; 林育麟; 鄭安理; 徐志宏; 許駿; 葉坤輝; 呂理駿 |
| 國立臺灣大學 |
2012 |
EXPLORING THE ANTI-TUMOR EFFICACY OF COMBINATION THERAPY WITH INHIBITORS TARGETING THE INSULIN-LIKE GROWTH FACTOR (IGF) AND PI3K/AKT/MTOR SIGNALING PATHWAYS FOR HEPATOCELLULAR CARCINOMA (HCC)
|
Ou, D. -L.; Hsu, C.; Lee, B. -S.; Chang, Y. -C.; Cheng, Y. -C.; Cheng, A. -L.; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2012 |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao, Y-Y; Lu, L-C; Lin, Z-Z; Hsu, C.; Shen, Y-C; Hsu, C-H; Cheng, A-L; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2012 |
THE ROLES OF GROWTH ARREST DNA DAMAGE-INDUCIBLE GENE 45 Gamma (GADD45 Gamma) EXPRESSION IN SORAFENIB-INDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA (HCC) CELLS
|
Hsu, C.; Ou, D. -L.; Shiau, C. -W.; Fan, H. -H.; Liao, S. -C.; Lin, Y. -Y.; Hsu, C. -H.; Cheng, A. -L.; 林育誼; 鄭安理; 徐志宏; 許駿; 歐大諒 |
| 國立臺灣大學 |
2012 |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo, Yu-Hsuan; Lin, Ching-Hung; Shau, Wen-Yi; Chen, Te-Jung; Yang, Shih-Hung; Huang, Shu-Min; Hsu, Chun; Lu, Yen-Shen; Cheng, Ann-Lii; 盧彥伸; 鄭安理; 許駿; 楊士弘; 林璟宏 |
| 國立臺灣大學 |
2012 |
Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma
|
Shau, Wen-Yi; Shao, Yu-Yun; Yeh, Yi-Chun; Lin, Zhong-Zhe; Kuo, Raymond; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; Lai, Mei-Shu; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2012 |
THE FIRST-TWO LINES OF CHEMOTHERAPY FOR DE NOVO METASTATIC BREAST CANCER: EFFICACY STUDY BETWEEN ANTHRACYCLINES AND NON-ANTHRACYCLINES
|
Chen, W. -W.; Chang, D. -Y.; Lin, C. -H.; Hsu, C.; Cheng, A. -L.; Lu, Y. -S.; 陳偉武; 盧彥伸; 鄭安理; 許駿; 張端瑩; 林璟宏 |
| 國立臺灣大學 |
2012 |
Changes of Pulmonary Fluorodeoxyglucose Uptake After Neoadjuvant Concurrent Chemoradiation in Predicting Postoperative Pulmonary Complications for Patients With Esophageal Cancer
|
Hsu, F.; Cheng, J.; Lee, J.; Huang, P.; Hsu, C.; Lin, C.; Tsai, Y.; Tzen, K.; Yen, R.; 曾凱元; 成佳憲; 顏若芳; 蔡育傑; 許駿; 李章銘; 黃培銘; 許峰銘 |
| 國立臺灣大學 |
2012 |
CHLORHEXIDINE FOR THE PREVENTION OF BLOODSTREAM INFECTION (BSI) ASSOCIATED WITH PERMANENTLY IMPLANTABLE VENOUS PORTS (PORT-A) IN SOLID CANCER PATIENTS: A PROSPECTIVE COHORT STUDY
|
Kao, H.; Chen, I.; Chang, S.; Hong, M.; Chien, S.; Hu, F.; Hsu, C.; Yeh, K.; 許駿 |
| 國立臺灣大學 |
2012 |
CYCLIN E1 SUPPRESSION CONTRIBUTES TO SORAFENIB-INDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA (HCC)
|
Hsu, C.; Ou, D.; Cheng, Y.; Lin, Y.; Chang, Y.; Yeh, K.; Cheng, A.; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2011 |
Activation of Checkpoint Kinase 2 (Chk2) Contributes to the Antitumour Synergy between Igf1 Receptor Kinase Inhibitor Nvp-Aew541 and Sunitinib in Hepatocellular Carcinoma
|
歐大諒; 沈盈君; 許駿; 鄭安理; OU, DA-LIANG; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010-07 |
多向度問卷之設計、翻譯與測試
|
季瑋珠; 許駿; 章殷超; 程劭儀; 高芷華 |
| 國立臺灣大學 |
2010 |
Bortezomib Suppresses Focal Adhesion Kinase Expression Via Interrupting Nuclear Factor-Kappa B
|
柯博升; 張孜菁; 陳建宏; 劉佳佳; 郭呈欽; 許駿; 沈盈君; 沈湯龍; 徐松錕; 劉俊揚; KO, BO-SHENG; CHANG, TZU-CHING; CHEN, CHIEN- HUNG; LIU, CHIA-CHIA; KUO, CHENG-CHIN; HSU, CHIUN; SHEN, YING-CHUN; SHEN, TANG-LONG; SHYUE, SONG-KUN; LIOU, JUN-YANG |
| 國立臺灣大學 |
2010 |
Adjuvant Interferon Therapy after Curative Therapy for Hepatocellular Carcinoma (Hcc): A Meta-Regression Approach
|
沈盈君; 許駿; 陳立宗; 鄭佳綺; 胡賦强; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; CHEN, LI-TZONG; CHENG, CHIA-CHI; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma
|
邵幼雲; 林宗哲; 許駿; 沈盈君; 徐志宏; 鄭安理; SHAO, YU-YUN; LIN, ZONG-ZHE; HSU, CHIUN; SHEN, YING-CHUN; HSU, CHIH-HUNG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Efficacy and Tolerability of Bevacizumab Plus Capecitabine as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
|
徐志宏; 許駿; 陳培哲; 林宗哲; 趙祖怡; 鄭安理; HSU, CHIH-HUNG; HSU, CHIUN; CHEN, PEI-JER; LIN, ZONG-ZHE; CHAO, TSU-YI; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (Dce-Mri) to Predict Treatment Outcomes for Advanced Hepatocellular Carcinoma (Hcc) Patients Who Received Sorafenib Plus Tegafur/Uracil Therapy
|
沈盈君; 許昭禹; 游治維; 許駿; 徐志宏; 鄭安理; 施庭芳; SHEN, YING-CHUN; HSU, CHAO-YU; YU, CHIH-WEI; HSU, CHIUN; HSU, CHIH-HUNG; CHENG, ANN-LII; SHIH, TIFFANY TING-FANG |
| 國立臺灣大學 |
2010 |
Geographic Difference in Survival Outcome for Advanced Hepatocellular Carcinoma: Implications on Future Clinical Trial Design
|
許駿; 沈盈君; 鄭佳綺; 胡賦强; 鄭安理; HSU, CHIUN; SHEN, YING-CHUN; CHENG, CHIA-CHI; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives
|
沈盈君; 許駿; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Phase Ii Study of Combining Sorafenib with Metronomic Tegafur/Uracil for Advanced Hepatocellular Carcinoma
|
徐志宏; 沈盈君; 林宗哲; 陳培哲; 邵幼雲; 丁雅慧; 許駿; 鄭安理; HSU, CHIH-HUNG; SHEN, YING-CHUN; LIN, ZONG-ZHE; CHEN, PEI-JER; SHAO, YU-YUN; DING, YEA-HUI; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Predictive and Prognostic Values of Tau and Ercc1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
|
邵幼雲; 郭冠廷; 胡賦强; 盧彥伸; 黃俊升; 廖肇裕; 許駿; 郭文宏; 張金堅; 林璟宏; 鄭安理; SHAO, YU-YUN; KUO, KUAN-TING; HU, FU-CHANG; LU, YEN-SHEN; HUANG, CHIUN-SHENG; LIAU, JAO-YU; HSU, CHIUN; KUO, WEN-HONG; CHANG, KING-JEN; LIN, CHING -HUNG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Preventive Effect of Anti-Viral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Meta -Regression Approach
|
鄭佳綺; 沈盈君; 許駿; 胡賦强; 鄭安理; CHENG, CHIA-CHI; SHEN, YING-CHUN; HSU, CHIUN; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Treatment Outcomes for Synchronous or Metachronous Hypopharyngeal/ Laryngeal/Oropharyngeal Cancer and Esophageal Cancer
|
許駿; 王駿瑋; 成佳憲; HSU, CHIUN; WANG, CHUN-WEI; CHENG, JASON CHIA-HSIEN |
| 國立臺灣大學 |
2010 |
Induction of DNA Damage-Inducible Gene Gadd45 Beta Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
|
歐大諒; 沈盈君; 俞松良; 陳昆鋒; 葉培彥; 林亮音; 許駿; 鄭安理; OU DA-LIANG; SHEN YING-CHUN; YU SUNG-LIANG; CHEN KUEN-FENG; YEH PEI-YEN; LIN LIANG-IN; HSU CHIUN; CHENG ANN-LII |
| 國立臺灣大學 |
2010 |
Design, Translation, and Test of Multi-Dimensional Questionnaires
|
季瑋珠; 許駿; 章殷超; 程劭儀; 高芷華; CHIE, WEI-CHU; HSU, CHIUN; Y.C.CHANG; CHEN, G SHAO-YI; KAO, TZE-WAH |
| 國立臺灣大學 |
2010 |
Potentiating the Anti-Tumor Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Signaling Pathway
|
歐大諒; 許駿; 沈盈君; 鄭安理; OU, DA-LIANG; HSU, CHIUN; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
The Aurora Kinase Inhibitor Ve-465 Has Anticancer Effects in Pre-Clinical Studies of Human Hepatocellular Carcinoma
|
許輝吉; 徐志宏; 葉培彥; 黃繼瑩; 郭頌鑫; 許駿; 胡賦強; 鄭永銘; 鄭安理; HSU, HEY-CHI; HSU, CHIH-HUNG; YEH, PEI-YEN; HUANG, CHI-YING; KUO, SUNG-HSIN; HSU, CHIUN; HU, FU-CHANG; JENG, YUNG-MING; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival
|
沈盈君; 胡賦強; 鄭永銘; 張毓廷; 林宗哲; 章明珠; 許駿; 鄭安理; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
INDUCTION OF BIM EXPRESSION CONTRIBUTES TO THE ANTITUMOR SYNERGY BETWEEN SORAFENIB AND MITOGEN-ACTIVATED PROTEIN KINASE/EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE INHIBITOR CI-1040 IN HEPATOCELLULAR CARCINOMA
|
歐大諒; 沈盈君; 梁嘉德; 劉俊陽; 俞松良; 盧彥伸; 許駿 |
顯示項目 36-85 / 148 (共3頁)
1 2 3 > >>
每頁顯示[10|25|50]項目
|
